René Vleugels

CyTuVax BV develops vaccinations for cancer treatment. Its vaccination technology includes an adjuvant composed of depot-bound cytokines acting as immune response modifiers. The firm also provides adjuvant technology licensing services. The company was founded by René Vleugels and Frank W. Falkenberg in 2011 and is headquartered in Maastricht, the Netherlands.

AdjuTec BV is a Dutch company that manufactures personalized therapeutic tumor vaccines for pancreatic and liver cancer patients. The company is based in Maastricht, Netherlands. The company was founded in 2017 by René Vleugels.

MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine.